medicines which can be substrates on the CYP3A enzyme as They could develop into significantly less powerful throughout treatment with JOURNAVX. Your healthcare supplier might have to adjust the dose of one's drugs when starting up or halting JOURNAVX Proleviate’s products are made

medicines that are substrates in the CYP3A enzyme as They might turn out to be significantly less efficient during treatment with JOURNAVX. Your healthcare service provider may need to regulate the dose of one's medicine when starting up or halting JOURNAVX Proleviate’s items are bu